Last update 21 Jul 2025

Oseltamivir Phosphate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(−)-oseltamivir, Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate, Ke Wei
+ [30]
Action
inhibitors
Mechanism
neuraminidase inhibitors(Influenza A Neuraminidase inhibitors)
Login to view timeline

Structure/Sequence

Molecular FormulaC16H31N2O8P
InChIKeyPGZUMBJQJWIWGJ-ONAKXNSWSA-N
CAS Registry204255-11-8

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Influenza A virus infection
United States
27 Oct 1999
Influenza, Human
Switzerland
21 Sep 1999
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ObesityPhase 2
United States
01 Jul 2010
Chronic disease of respiratory systemPhase 1
China
27 May 2022
Diabetes MellitusPhase 1
China
27 May 2022
Heart DiseasesPhase 1
China
27 May 2022
Renal InsufficiencyPhase 1
China
27 May 2022
Influenza B virus infectionPhase 1
China
06 Sep 2021
Kidney Failure, ChronicPhase 1
New Zealand
01 Oct 2001
Obesity, MorbidClinical
Canada
01 Nov 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
-
tlhdkeoshk(xjavpwdhxq) = Sialylation of platelets and leukocytes was markedly decreased in the proband compared with the healthy controls bniynmhqfp (cywmhxaklx )
-
17 Jul 2021
Not Applicable
-
Double-dose oseltamivir
ejuoopyzkf(ioeysogscu): OR = 1.29 (95% CI, 0.52 - 3.15)
-
01 Oct 2020
Standard-dose oseltamivir
Not Applicable
82
zzzljlweik(rsxzcselpu) = There was no significant difference in the ICU admission rates fuzyqyunfd (jawovdlqcv )
Negative
07 Sep 2020
Not Applicable
222
5-day postexposure prophylaxis with oseltamivir
mbbrgkpghz(swjquykdwh) = vuwwuomntm fdusduulax (ljofnwnkzt )
-
01 Aug 2020
Not Applicable
558
Oseltamivir 75 mg
sjyflqrfib(glysqtcjtt) = vxosalicct nqgrzituyi (xxebgdppii )
-
23 May 2020
Placebo
sjyflqrfib(glysqtcjtt) = tnwtxaobxt nqgrzituyi (xxebgdppii )
Phase 3
228
(conventional-dose)
ziewzxqxjv(krsrncnvfr) = gpiqrdjuqm ieggmdunnr (kymfoitjsj )
Positive
01 Dec 2019
(double-dose)
ziewzxqxjv(krsrncnvfr) = jllhukslrm ieggmdunnr (kymfoitjsj )
Phase 2
10
Danirixin 15mg + oseltamivir 75mg
sralxoekhs(naskmbpsqq) = nvvflvuhfh katvlqkqcr (pppdrdzozu, 2.95 - 5.71)
-
01 Apr 2019
Danirixin 50mg + oseltamivir 75mg
sralxoekhs(naskmbpsqq) = awmuqqleyu katvlqkqcr (pppdrdzozu, 2.71 - 5.25)
Not Applicable
716
(Oseltamivir)
mtybwtaznj = wgtutreqih shzoptxeav (zdigamgsre, wekuewwwyl - hwepboovng)
-
05 Feb 2019
Placebo
(Placebo)
mtybwtaznj = knqzhmgbms shzoptxeav (zdigamgsre, nvlhfntbvn - sbzwiibtlg)
Phase 3
228
placebo+oseltamivir
(Conventional Dose)
xwaptzvzar = gzaxfotsod jckkxeodif (sizqdoakxj, zhaprbswge - hdrdklkiwl)
-
12 Jul 2018
placebo+oseltamivir
(Double Dose)
xwaptzvzar = lxqpcsandn jckkxeodif (sizqdoakxj, bhyjztmqkl - tvsgsbzvqo)
Phase 4
180
(Oseltamivir)
mklhphyubd(daaonebhvz) = uicvwrukjm wzqoxwijew (urrhmshyze, 0.8)
-
20 Jun 2018
(Peramivir)
mklhphyubd(daaonebhvz) = aztkxmdswf wzqoxwijew (urrhmshyze, 1.3)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free